Denosumab for myeloma bone disease: ready for prime time?
Mené dans 29 pays sur 1 718 patients atteints d'un myélome multiple récemment diagnostiqué, cet essai de phase III compare la toxicité et l'efficacité du dénosumab et de l'acide zolédronique pour prévenir les événements indésirables liés au squelette
Increased osteoclast activity is the hallmark of myeloma bone disease and RANKL is the most potent osteoclast activator. Bisphosphonates and monoclonal antibodies targeting RANKL (eg, denosumab) inhibit osteoclasts and are the mainstay of therapy of cancer-related bone disease. Bisphosphonates reduce skeletal-related events. Zoledronic acid, a potent bisphosphonate, improved survival compared with clodronate of patients with myeloma in a large study1 that used thalidomide-based or conventional chemotherapy.
The Lancet Oncology , commentaire, 2017